NASDAQ:DRRX - DURECT Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $1.48 -0.03 (-1.99 %) (As of 07/20/2018 12:36 PM ET)Previous Close$1.53Today's Range$1.48 - $1.5352-Week Range$0.75 - $2.55Volume12,224 shsAverage Volume1.00 million shsMarket Capitalization$242.56 millionP/E Ratio-50.67Dividend YieldN/ABeta1.29 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials in their products for pharmaceutical and medical devices under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's advanced oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including REMOXY ER, an investigational extended release pain relief drug based on ORADUR technology; and POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has collaboration agreements with Sandoz AG; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Zogenix, Inc.; and Pain Therapeutics, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California. Receive DRRX News and Ratings via Email Sign-up to receive the latest news and ratings for DRRX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:DRRX CUSIPN/A Webwww.durect.com Phone408-777-1417 Debt Debt-to-Equity Ratio0.50 Current Ratio4.61 Quick Ratio4.32 Price-To-Earnings Trailing P/E Ratio-50.67 Forward P/E Ratio-6.43 P/E GrowthN/A Sales & Book Value Annual Sales$49.17 million Price / Sales4.87 Cash FlowN/A Price / CashN/A Book Value$0.14 per share Price / Book10.57 Profitability EPS (Most Recent Fiscal Year)($0.03) Net Income$-3,690,000.00 Net Margins-8.06% Return on Equity-25.82% Return on Assets-7.04% Miscellaneous Employees93 Outstanding Shares161,710,000Market Cap$242.56 DURECT (NASDAQ:DRRX) Frequently Asked Questions What is DURECT's stock symbol? DURECT trades on the NASDAQ under the ticker symbol "DRRX." How were DURECT's earnings last quarter? DURECT Co. (NASDAQ:DRRX) released its quarterly earnings results on Wednesday, May, 2nd. The specialty pharmaceutical company reported ($0.05) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.06) by $0.01. The specialty pharmaceutical company earned $3.49 million during the quarter, compared to analyst estimates of $4.20 million. DURECT had a negative return on equity of 25.82% and a negative net margin of 8.06%. View DURECT's Earnings History. When is DURECT's next earnings date? DURECT is scheduled to release their next quarterly earnings announcement on Tuesday, August, 14th 2018. View Earnings Estimates for DURECT. What price target have analysts set for DRRX? 3 equities research analysts have issued 12-month price objectives for DURECT's stock. Their predictions range from $2.00 to $3.50. On average, they anticipate DURECT's stock price to reach $2.75 in the next year. This suggests a possible upside of 84.6% from the stock's current price. View Analyst Ratings for DURECT. What is the consensus analysts' recommendation for DURECT? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." Who are some of DURECT's key competitors? Some companies that are related to DURECT include Omeros (OMER), CytomX Therapeutics (CTMX), Epizyme (EPZM), Karyopharm Therapeutics (KPTI), MacroGenics (MGNX), TG Therapeutics Inc common stock (TGTX), Rhythm Pharmaceuticals (RYTM), Assembly Biosciences (ASMB), Amarin (AMRN), ANI Pharmaceuticals Inc Common Stock (ANIP), Inflarx (IFRX), Rocket Pharmaceuticals (RCKT), Homology Medicines (FIXX), NuCana (NCNA) and Eidos Therapeutics (EIDX). Who are DURECT's key executives? DURECT's management team includes the folowing people: Dr. Felix Theeuwes, Co-Founder, Chairman & Distinguished Scientist (Age 80)Dr. James E. Brown, Co-Founder, CEO, Pres & Director (Age 61)Mr. Matthew J. Hogan, CFO & Sec. (Age 58)Ms. Judy R. Joice, Sr. VP of Operations & Corp. Quality Assurance (Age 61)Mr. Michael H. Arenberg J.D., M.B.A., Sr. VP of Corp. & Bus. Devel. Has DURECT been receiving favorable news coverage? Press coverage about DRRX stock has trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. DURECT earned a daily sentiment score of 0.14 on Accern's scale. They also assigned media headlines about the specialty pharmaceutical company an impact score of 47.08 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days. How do I buy shares of DURECT? Shares of DRRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is DURECT's stock price today? One share of DRRX stock can currently be purchased for approximately $1.49. How big of a company is DURECT? DURECT has a market capitalization of $242.56 million and generates $49.17 million in revenue each year. The specialty pharmaceutical company earns $-3,690,000.00 in net income (profit) each year or ($0.03) on an earnings per share basis. DURECT employs 93 workers across the globe. How can I contact DURECT? DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The specialty pharmaceutical company can be reached via phone at 408-777-1417. MarketBeat Community Rating for DURECT (NASDAQ DRRX)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 181 (Vote Outperform)Underperform Votes: 116 (Vote Underperform)Total Votes: 297MarketBeat's community ratings are surveys of what our community members think about DURECT and other stocks. Vote "Outperform" if you believe DRRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRRX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: Are Wall Street analysts' stock ratings worth following?